Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • ROOMS:

Nasopharyngeal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Incyte, BeiGene, Klus Pharma, Merck, Roche, Novartis, Akeso Pharma

Nasopharyngeal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Incyte, BeiGene, Klus Pharma, Merck, Roche, Novartis, Akeso Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Nasopharyngeal Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Nasopharyngeal Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Nasopharyngeal Cancer Market. 

The Nasopharyngeal Cancer Pipeline report embraces in-depth commercial, regulatory, and Nasopharyngeal Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Nasopharyngeal Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Nasopharyngeal Cancer Pipeline Analysis

Nasopharyngeal Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Nasopharyngeal Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Nasopharyngeal Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Nasopharyngeal Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Nasopharyngeal Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Nasopharyngeal Cancer therapeutics market.

Analysis of Emerging Nasopharyngeal Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Subcutaneous

  • Intravenous

  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Bispecific Antibody

  • Peptides

  • Small molecule

  • Gene therapy

Learn How the Nasopharyngeal Cancer Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Nasopharyngeal Cancer Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Nasopharyngeal Cancer. Currently, Innovent Biologics is leading the therapeutics market with its Nasopharyngeal Cancer drug candidates in the most advanced stage of clinical development.

Nasopharyngeal Cancer Companies Actively Working in the Therapeutic Market Include:

  • Akeso Pharmaceuticals, Inc.

  • Atara biotherapeutics

  • BeiGene

  • Betta Pharmaceuticals Co., Ltd.

  • Bristol-Myers Squibb

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  • Hoffman La Roche

  • Incyte Corporation

  • innovent Biologics

  • Jiangsu HengRui Medicine Co., Ltd.

  • Klus Pharma

  • Merck Sharp & Dohme Corp.

  • Novartis Pharmaceuticals

  • Tessa Therapeutics

And Many Others

Emerging and Marketed Nasopharyngeal Cancer Drugs Covered in the Report Include:

  • Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.

  • Tislelizumab: BioGene

  • Tabelecleucel: Atara Biotherapeutics Inc.

  • PDR001: Novartis Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Nasopharyngeal Cancer Companies Working in the Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Nasopharyngeal Cancer Treatment Patterns

4. Nasopharyngeal Cancer - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Nasopharyngeal Cancer Late Stage Products (Phase-III)

7. Nasopharyngeal Cancer Mid-Stage Products (Phase-II)

8. Nasopharyngeal Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nasopharyngeal Cancer Discontinued Products

13. Nasopharyngeal Cancer Product Profiles

14. Major Nasopharyngeal Cancer Companies in the Market

15. Key Products in the Nasopharyngeal Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Nasopharyngeal Cancer Unmet Needs

18. Nasopharyngeal Cancer Future Perspectives

19. Nasopharyngeal Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 


Other Trending Healthcare Reports By DelveInsight

Deep Brain Stimulation Devices Market

Global Deep Brain Stimulation Devices (DBS) Market was valued at USD 1.31 billion in 2021 and growing at a CAGR of 10.40% during the forecast period (2023 to 2028); it is expected to reach USD 2.37 billion by 2028. The Deep Brain Stimulation Devices Market is expected to grow owing to the growing prevalence of movement disorders such as Parkinson’s disease, expansion of disease indications for DBS therapy, rising geriatric population, and increasing research and development activities in product development, among other factors.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photography by Christophe Tomatis
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.